Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance
Authors:
Open Access
- 15 November 2013
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (3) , 511-518
Abstract
Multiple myeloma still remains incurable in the majority of cases prompting a further search for new and better prognostic markers. Emerging evidence has suggested that circulating microRNAs can serve as minimally invasive biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. In this study, a global analysis of serum microRNAs by TaqMan Low Density Arrays was performed, followed by quantitative real-time PCR. The analyses revealed five deregulated microRNAs: miR-744, miR-130a, miR-34a, let-7d and let-7e in monoclonal gammopathy of undetermined significance, newly diagnosed and relapsed multiple myeloma when compared to healthy donors. Multivariate logistical regression analysis showed that a combination of miR-34a and let-7e can distinguish multiple myeloma from healthy donors with a sensitivity of 80.6% and a specificity of 86.7%, and monoclonal gammopathy of undetermined significance from healthy donors with a sensitivity of 91.1% and a specificity of 96.7%. Furthermore, lower levels of miR-744 and let-7e were associated with shorter overall survival and remission of myeloma patients. One-year mortality rates for miR-744 and let-7e were 41.9% and 34.6% for the ‘low’ expression and 3.3% and 3.9% for the ‘high’ expression groups, respectively. Median time of remission for both miR-744 and let-7e was approximately 11 months for the ‘low’ expression and approximately 47 months for the ‘high’ expression groups of myeloma patients These data demonstrate that expression patterns of circulating microRNAs are altered in multiple myeloma and monoclonal gammopathy of undetermined significance and miR-744 with let-7e are associated with survival of myeloma patients.Keywords
This publication has 43 references indexed in Scilit:
- Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myelomaBritish Journal of Cancer, 2012
- Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma:In VitroandIn VivoEvidenceClinical Cancer Research, 2012
- Secreted microRNAs: a new form of intercellular communicationTrends in Cell Biology, 2012
- Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disordersBlood Cancer Journal, 2012
- Circulating microRNAs: Association with disease and potential use as biomarkersCritical Reviews in Oncology/Hematology, 2011
- Characterization of extracellular circulating microRNANucleic Acids Research, 2011
- MicroRNAs regulate critical genes associated with multiple myeloma pathogenesisProceedings of the National Academy of Sciences, 2008
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- Multiple myelomaBlood, 2008
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006